• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Actym Therapeutics Appoints Thomas Smart as CEO

    4/24/24 9:00:00 AM ET
    $ANAB
    $PGEN
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANAB alert in real time by email

    BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

    (PRNewsfoto/Actym Therapeutics Inc.)

    Actym's proprietary platform, S. Typhimurium-Attenuated Cancer Therapy (STACT), represents a novel approach to achieving comprehensive immunological reprogramming of the tumor microenvironment. Mr. Smart's appointment follows Actym's recent presentations of preclinical data at both the 2023 SITC and 2024 AACR Annual Meetings showcasing ACTM-838's ability to selectively accumulate in the TME and locally deliver two potent payloads, engineered IL-15 and engineered STING.

    "Tom is an extremely valuable addition to Actym's leadership, bringing extensive experience in corporate development and strategic planning, coupled with a profound understanding of how to translate innovative R&D into novel therapeutics. With Tom at the helm, we are ready for our next stage of corporate growth as we close in on the start of our Phase 1 clinical development program for ACTM-838," said Julie Cherrington, Ph.D., Executive Chair of the Actym Board of Directors. "We extend our thanks to Chris Thanos for his founding contributions to the company."

    "Actym represents an exceptional opportunity to achieve a new level of therapeutic impact across multiple tumor types. In addition to moving ACTM-838 into the clinic in the second quarter, our goal is to expand our pipeline with additional candidates from Actym's modular platform. The STACT approach provides both efficacy and safety advantages by leveraging a genetically modified bacteria vehicle, systemically administered, that achieves tissue-specific delivery of large nucleic acid payloads," said Thomas Smart, CEO of Actym. "I look forward to collaborating with the Board of Directors and the entire Actym team to maximize the potential of ACTM-838 and our platform."

    Mr. Smart has a distinguished 25-year career as a biotech executive, demonstrating dynamic leadership in roles such as CEO, CBO, SVP, and Board Member. In addition, Mr. Smart has a comprehensive background in therapeutic modalities ranging from antibodies and small molecules to peptides, RNA, DNA, CAR-T, and other cell therapies. Before joining Actym Therapeutics, Mr. Smart founded Gravitas Therapeutics, where he served as CEO and Board Chair and orchestrated the acquisition and subsequent sale of the clinical-stage antifungal asset, GR-2397, to Basilea Pharmaceutica Ltd (SIX: BSLN) in October 2023. His prior leadership roles include serving as CEO and Board Chair of AnaptysBio (NASDAQ:ANAB), Chief Business Officer of XOMA (NASDAQ:XOMA), and various positions at Genetics Institute (now Pfizer), GenVec ((now Precigen, NASDAQ:PGEN), Searle (now Pfizer), and Cell Genesys. Mr. Smart holds a Bachelor of Science degree from Cornell University and earned his Master of Business Administration from the University of Chicago Booth School of Business.

    About Actym

    Actym Therapeutics has engineered a new drug modality harnessing the power of a genetically modified bacterial vehicle that safely introduces therapeutic payloads to activate the immune response in the tumor microenvironment. To achieve targeted anti-tumor effects, we have developed a systemically administered treatment that exploits intrinsic TME-specific metabolites, enabling selective enrichment of the bacterial vehicle in tumors. After cell-specific entry, our lead candidate, ACTM-838, positively activates tumor-resident myeloid cells and delivers two synergistic payloads, optimized IL-15 and STING, unlocking a comprehensive and durable innate and adaptive anti-tumor immune response. With the ability to tailor our platform utilizing a range of payload combinations, we aim to achieve a new level of therapeutic impact for cancer patients across multiple tumor types.

    Contacts

    For Actym Therapeutics

    Thomas E. Smart, CEO

    E-Mail: [email protected]

    Media Requests for Actym

    Dr. Alison Opalko or Sara Ortiz

    Trophic Communications

    Phone: +49 151 54041130 or +49 160 90816161

    E-Mail: [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/actym-therapeutics-appoints-thomas-smart-as-ceo-302125751.html

    SOURCE Actym Therapeutics Inc.

    Get the next $ANAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANAB
    $PGEN
    $XOMA

    CompanyDatePrice TargetRatingAnalyst
    Precigen Inc.
    $PGEN
    8/15/2025Underweight → Neutral
    Analyst
    AnaptysBio Inc.
    $ANAB
    6/4/2025$38.00Neutral → Buy
    H.C. Wainwright
    XOMA Royalty Corporation
    $XOMA
    4/17/2025$35.00Buy
    The Benchmark Company
    AnaptysBio Inc.
    $ANAB
    2/4/2025$25.00Outperform
    Wolfe Research
    AnaptysBio Inc.
    $ANAB
    12/11/2024$52.00 → $19.00Buy → Neutral
    H.C. Wainwright
    AnaptysBio Inc.
    $ANAB
    12/2/2024Buy → Neutral
    BTIG Research
    AnaptysBio Inc.
    $ANAB
    7/22/2024$55.00Buy
    H.C. Wainwright
    AnaptysBio Inc.
    $ANAB
    7/19/2024$29.00 → $69.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $ANAB
    $PGEN
    $XOMA
    SEC Filings

    View All

    AnaptysBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ANAPTYSBIO, INC (0001370053) (Filer)

    9/29/25 4:29:55 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Precigen Inc.

    144 - PRECIGEN, INC. (0001356090) (Subject)

    9/29/25 4:12:32 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by XOMA Royalty Corporation

    8-K - XOMA Royalty Corp (0000791908) (Filer)

    9/26/25 5:29:26 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    $PGEN
    $XOMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Precigen upgraded by Analyst

    Analyst upgraded Precigen from Underweight to Neutral

    8/15/25 8:13:17 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AnaptysBio upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded AnaptysBio from Neutral to Buy and set a new price target of $38.00

    6/4/25 7:31:04 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Benchmark Company initiated coverage on XOMA Royalty Corporation with a new price target

    The Benchmark Company initiated coverage of XOMA Royalty Corporation with a rating of Buy and set a new price target of $35.00

    4/17/25 8:34:06 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    $PGEN
    $XOMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

    Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their valueUpon completion, the biopharma operations company will focus on development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033 and ANB101Company to host a conference call with investors today at 4:30pm ET/1:30pm PT SAN DIEGO, Sept. 29

    9/29/25 4:05:49 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

    SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB033, its CD122 antagonist, at 4:30pm ET / 1:30pm PT on Tuesday, Oct. 14. The event will include Joseph A. Murray, M.D., professor of medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, and Department of Immunology at the Mayo Clinic, along with members of the Anaptys management team. The event will cover: ANB033's mechanism of action, an antagonist of the CD122 receptorPreclinical data and initial Phase 1a data in healt

    9/29/25 4:05:46 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA Pharma Inc. Amends Agreement with XenoTherapeutics

    Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting to October 3, 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 24, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that it has reached an agreement to amend its previously announced Business Combination Agreement (the "Amended Agreement") with XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company. XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) continues to act as structuring agent and intends to provide financing for the transac

    9/24/25 6:00:00 AM ET
    $EPIX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    $PGEN
    $XOMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Thomasian Harry Jr. bought $40,016 worth of shares (11,216 units at $3.57), increasing direct ownership by 2% to 468,626 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/26/25 5:01:54 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Investment Officer Sitko Bradley converted options into 6,712 shares, increasing direct ownership by 51% to 19,822 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    9/23/25 5:32:53 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Hughes Owen converted options into 35,567 shares, increasing direct ownership by 57% to 98,268 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    9/23/25 5:32:38 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    $PGEN
    $XOMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Thomasian Harry Jr. bought $40,016 worth of shares (11,216 units at $3.57), increasing direct ownership by 2% to 468,626 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/26/25 5:01:54 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Agee Nancy H bought $69,000 worth of shares (15,000 units at $4.60), increasing direct ownership by 7% to 217,841 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/5/25 5:46:22 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Agee Nancy H bought $98,643 worth of shares (26,005 units at $3.79), increasing direct ownership by 15% to 202,841 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    8/29/25 4:21:18 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    $PGEN
    $XOMA
    Financials

    Live finance-specific insights

    View All

    Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

    Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their valueUpon completion, the biopharma operations company will focus on development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033 and ANB101Company to host a conference call with investors today at 4:30pm ET/1:30pm PT SAN DIEGO, Sept. 29

    9/29/25 4:05:49 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Declares Quarterly Preferred Stock Dividends

    EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock:   Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share.   Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.   The preferred dividends will be paid on or about October 15, 2025, t

    9/22/25 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

    WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company ("Mural"), and XOMA Royalty Corporation (NASDAQ:XOMA), a biotechnology royalty aggregator ("XOMA Royalty"), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty ("Sub"), has agreed to acquire the entire issued and to be issued share capital of Mural for cash (the "Acquisition") subject to the satisfaction of the closing conditions set out in Appendix I of this Announcement (the "Conditions"), including approval by Mural Shareholders. Fol

    8/20/25 8:30:00 AM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    $PGEN
    $XOMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

    SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

    11/14/24 4:00:05 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

    SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

    11/14/24 9:24:47 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by AnaptysBio Inc.

    SC 13D/A - ANAPTYSBIO, INC (0001370053) (Subject)

    8/16/24 12:07:11 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    $PGEN
    $XOMA
    Leadership Updates

    Live Leadership Updates

    View All

    Precigen Reports First Quarter 2025 Financial Results and Business Updates

    PRGN-2012 has the potential to be the first- and best-in-class treatment for RRPCompany's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the USCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11Cash, cash equivalents, and investments of $81.0 million as of March 31, 20

    5/14/25 4:05:00 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

    SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

    4/17/25 7:00:00 AM ET
    $ANAB
    $DSGN
    $PSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Business Services

    Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

    – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

    4/16/25 8:05:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care